Celldex Therapeutics Future Growth
Future criteria checks 2/6
Celldex Therapeutics is forecast to grow earnings and revenue by 1.1% and 74.8% per annum respectively. EPS is expected to grow by 5.5% per annum. Return on equity is forecast to be -169.5% in 3 years.
Key information
1.1%
Earnings growth rate
5.5%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 74.8% |
| Future return on equity | -169.5% |
| Analyst coverage | Good |
| Last updated | 20 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3 | -266 | -234 | -190 | 7 |
| 12/31/2025 | 4 | -223 | -165 | -170 | 10 |
| 12/31/2024 | 7 | -160 | -157 | -143 | 10 |
| 9/30/2024 | 10 | -154 | -160 | -158 | N/A |
| 6/30/2024 | 8 | -150 | -123 | -121 | N/A |
| 3/31/2024 | 6 | -145 | -121 | -119 | N/A |
| 12/31/2023 | 7 | -141 | -109 | -107 | N/A |
| 9/30/2023 | 4 | -125 | -98 | -97 | N/A |
| 6/30/2023 | 3 | -113 | -114 | -113 | N/A |
| 3/31/2023 | 3 | -119 | -110 | -108 | N/A |
| 12/31/2022 | 2 | -112 | -106 | -104 | N/A |
| 9/30/2022 | 1 | -106 | -98 | -96 | N/A |
| 6/30/2022 | 1 | -100 | -79 | -78 | N/A |
| 3/31/2022 | 4 | -77 | -69 | -67 | N/A |
| 12/31/2021 | 5 | -71 | -62 | -61 | N/A |
| 9/30/2021 | 8 | -72 | -53 | -52 | N/A |
| 6/30/2021 | 9 | -66 | -48 | -47 | N/A |
| 3/31/2021 | 5 | -64 | -48 | -46 | N/A |
| 12/31/2020 | 7 | -60 | -42 | -40 | N/A |
| 9/30/2020 | 5 | -48 | -48 | -46 | N/A |
| 6/30/2020 | 4 | -46 | -47 | -45 | N/A |
| 3/31/2020 | 5 | -46 | -46 | -45 | N/A |
| 12/31/2019 | 4 | -51 | -47 | -46 | N/A |
| 9/30/2019 | 4 | -50 | -52 | -51 | N/A |
| 6/30/2019 | 5 | -46 | -55 | -54 | N/A |
| 3/31/2019 | 7 | -50 | -61 | -60 | N/A |
| 12/31/2018 | 10 | -151 | -76 | -75 | N/A |
| 9/30/2018 | 11 | -146 | -80 | -79 | N/A |
| 6/30/2018 | 14 | -165 | N/A | -89 | N/A |
| 3/31/2018 | 15 | -177 | N/A | -93 | N/A |
| 12/31/2017 | 13 | -93 | N/A | -100 | N/A |
| 9/30/2017 | 11 | -121 | N/A | -101 | N/A |
| 6/30/2017 | 9 | -125 | N/A | -100 | N/A |
| 3/31/2017 | 7 | -128 | N/A | -113 | N/A |
| 12/31/2016 | 7 | -129 | N/A | -113 | N/A |
| 9/30/2016 | 7 | -129 | N/A | -106 | N/A |
| 6/30/2016 | 6 | -131 | N/A | -110 | N/A |
| 3/31/2016 | 6 | -132 | N/A | -101 | N/A |
| 12/31/2015 | 5 | -127 | N/A | -99 | N/A |
| 9/30/2015 | 5 | -126 | N/A | -107 | N/A |
| 6/30/2015 | 5 | -122 | N/A | -106 | N/A |
| 3/31/2015 | 4 | -118 | N/A | -102 | N/A |
| 12/31/2014 | 4 | -118 | N/A | -102 | N/A |
| 9/30/2014 | 3 | -108 | N/A | -94 | N/A |
| 6/30/2014 | 3 | -103 | N/A | -85 | N/A |
| 3/31/2014 | 2 | -94 | N/A | -82 | N/A |
| 12/31/2013 | 4 | -82 | N/A | -68 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TCE2 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TCE2 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TCE2 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TCE2's revenue (74.8% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: TCE2's revenue (74.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TCE2 is forecast to be unprofitable in 3 years.